5T4 oncofoetal antigen: an attractive target for immune intervention in cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Cancer progression involves genetic diversity and clonal dominance, complicating targeted therapies.
• The 5T4 oncofoetal antigen, shared by trophoblast and cancer cells, is a potential target for cancer intervention.
• 5T4 expression is linked to tumor spread through mechanisms like epithelial-mesenchymal transition and altered Wnt signaling.

Purpose of the Study:

• To investigate the 5T4 oncofoetal antigen as a target for cancer immunotherapy.
• To review the role of 5T4 in cancer progression and its potential for therapeutic strategies.
• To discuss the development of various 5T4-targeted immunotherapies and future challenges.

Main Methods:

• Identification of 5T4 by searching for surface molecules on trophoblast and cancer cells.
• Analysis of 5T4 protein characteristics, including glycosylation and leucine-rich repeats.
• Review of studies linking 5T4 expression to cancer cell movement, chemotaxis, and signaling pathways.

Main Results:

• 5T4 is expressed on many cancers but rarely in normal adult tissues, making it a selective tumor target.
• 5T4 expression is associated with epithelial mesenchymal transition, CXCL12/CXCR4 chemotaxis, and Wnt pathway alterations, promoting cancer spread.
• Multiple immunotherapeutic strategies targeting 5T4 are in development, including vaccines, antibody drug conjugates, and CAR T-cell therapy.

Conclusions:

• The 5T4 antigen's selective tumor expression and role in cancer progression support its use in targeted immunotherapies.
• Various 5T4-targeted therapies, including vaccines and antibody conjugates, are advancing towards clinical application.
• Combining 5T4 immunotherapies with standard treatments is crucial for maximizing immune control and achieving tumor elimination.